[go: up one dir, main page]

AR091185A1 - Derivados de 1,2,4-triazol - Google Patents

Derivados de 1,2,4-triazol

Info

Publication number
AR091185A1
AR091185A1 ARP130101863A AR091185A1 AR 091185 A1 AR091185 A1 AR 091185A1 AR P130101863 A ARP130101863 A AR P130101863A AR 091185 A1 AR091185 A1 AR 091185A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
optionally substituted
heterocycloalkyl
haloalkyl
Prior art date
Application number
Other languages
English (en)
Inventor
Schaffhauser Herve
Groebke Zbinden Katrin
Kuhn Bernd
Lerner Christian
Flohr Alexander
Rudolph Markus
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48534382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR091185(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR091185A1 publication Critical patent/AR091185A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Estos compuestos inhiben la PDE10A y pueden utilizarse como medicamentos. Reivindicación 1: Un compuesto de la fórmula (1) ó (2) en las que: B es alquileno C₁₋₄, alquenileno C₂₋₄, alquinileno C₂₋₄, cicloalquilo C₃₋₅; R¹ y R² se eligen con independencia entre hidrógeno, alquilo C₁₋₇ opcionalmente sustituido por cicloalquilo C₃₋₅; hidroxialquilo C₁₋₇, alcoxialquilo C₁₋₇, haloalquilo C₁₋₇, cicloalquilo C₃₋₅, R¹ y R² junto con el átomo de nitrógeno, al que están unidos, forman un azaespirocicloalquilo, un anillo bicíclico o un heterocicloalquilo que pueden estar sustituidos de 1 a 3 veces por sustituyentes elegidos con independencia entre el grupo formado por halógeno, alquilo C₁₋₇, alcoxialquilo C₁₋₇; hidroxi-alquilo C₁₋₇, alcoxi C₁₋₇, haloalquilo C₁₋₇, hidroxilo, -NR⁹R¹⁰ y oxo; R³ se elige entre hidrógeno, cicloalquilo C₃₋₅, alcoxialquilo C₁₋₇, haloalquilo C₁₋₇, heterocicloalquilo, -(CH₂)₀,₁,₂-arilo opcionalmente sustituido por alcoxi C₁₋₇ y alquilo C₁₋₇ opcionalmente sustituido por cicloalquilo C₃₋₅; R⁴ se elige entre heteroarilo opcionalmente sustituido de 1 a 3 veces por sustituyentes elegidos entre halógeno, alquilo C₁₋₇, hidroxialquilo C₁₋₇, haloalcoxi C₁₋₇, halo-alquilo C₁₋₇, cicloalquilo C₃₋₅, ciano, amino, nitro, -O-R⁶-C(O)-R⁷, -SO₂R⁸, alcoxi C₁₋₂ opcionalmente sustituido por alcoxi C₁₋₂, heterocicloalquilo; R⁶ y R⁸ se eligen entre alquilo C₁₋₇; R⁷ se elige entre heterocicloalquilo; R⁹ y R¹⁰ se eligen con independencia entre hidrógeno, alquilo C₁₋₇, -C(O)-O-alquilo C₁₋₇.
ARP130101863 2012-05-30 2013-05-29 Derivados de 1,2,4-triazol AR091185A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12169954 2012-05-30

Publications (1)

Publication Number Publication Date
AR091185A1 true AR091185A1 (es) 2015-01-14

Family

ID=48534382

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101863 AR091185A1 (es) 2012-05-30 2013-05-29 Derivados de 1,2,4-triazol

Country Status (21)

Country Link
US (1) US9394311B2 (es)
EP (1) EP2855455B1 (es)
JP (1) JP5992096B2 (es)
KR (1) KR101666293B1 (es)
CN (1) CN104364249B (es)
AR (1) AR091185A1 (es)
AU (1) AU2013269800A1 (es)
BR (1) BR112014026828A2 (es)
CA (1) CA2868240A1 (es)
CL (1) CL2014002847A1 (es)
CO (1) CO7091174A2 (es)
CR (1) CR20140481A (es)
EA (1) EA201492069A1 (es)
IL (1) IL235829A0 (es)
MX (1) MX2014014468A (es)
PE (1) PE20142366A1 (es)
PH (1) PH12014502294A1 (es)
SG (1) SG11201406890YA (es)
TW (1) TW201402564A (es)
WO (1) WO2013178572A1 (es)
ZA (1) ZA201407695B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2888324A1 (en) * 2012-11-07 2014-05-15 Alexander Flohr Triazolo compounds
CA3042380A1 (en) 2016-11-03 2018-05-24 Bristol-Myers Squibb Company Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors
CN111875583B (zh) * 2017-10-17 2021-06-15 中国科学院上海药物研究所 三氮唑衍生物及其制备方法和用途
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
SG11202013216RA (en) 2018-07-05 2021-01-28 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
BR112020013820A2 (pt) 2018-11-06 2021-06-01 H. Lundbeck A/S inibidores de pde10a para tratamento de sintomas negativos e comprometimentos cognitivos em um paciente sofrendo de esquizofrenia
BR112020013697A2 (pt) 2018-11-06 2020-12-01 H. Lundbeck A/S compostos para tratamento de sintomas negativos e comprometimentos cognitivos
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2021059220A1 (en) * 2019-09-25 2021-04-01 Oncoarendi Therapeutics S.A. Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine
CN113929634A (zh) * 2021-11-22 2022-01-14 山西永津集团有限公司 一种2,3-二溴喹喔啉的合成方法
EP4488270A1 (en) 2023-07-06 2025-01-08 Basf Se Triazole compounds for the control of invertebrate pests
WO2025008250A1 (en) 2023-07-06 2025-01-09 Basf Se Triazole compounds for the control of invertebrate pests

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2744116A (en) * 1953-12-04 1956-05-01 Purdue Research Foundation Bis-(aminotriazolyl-)-hydrocarbons
AR022229A1 (es) * 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
US6887870B1 (en) * 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
EP1885713A1 (en) * 2005-05-18 2008-02-13 Pfizer Limited 1, 2, 4 -triazole derivatives as vasopressin antagonists
PE20070405A1 (es) * 2005-08-10 2007-05-06 Smithkline Beecham Corp Compuestos derivados de xantina como agonistas del receptor de acido nicotinico hm74a
WO2008103357A1 (en) * 2007-02-21 2008-08-28 E. I. Du Pont De Nemours And Company Fungicidal tricyclic 1,2,4-triazoles
KR101156845B1 (ko) * 2007-05-21 2012-06-18 에스지엑스 파마슈티컬스, 인코포레이티드 헤테로시클릭 키나제 조절제
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
TWI487705B (zh) * 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
WO2011150156A2 (en) * 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
HUE033378T2 (en) * 2010-08-12 2017-11-28 Boehringer Ingelheim Int 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
WO2012054366A2 (en) * 2010-10-21 2012-04-26 Merck Sharp & Dohme Corp. Substituted amino-triazolyl pde10 inhibitors

Also Published As

Publication number Publication date
EA201492069A1 (ru) 2015-03-31
CN104364249B (zh) 2018-04-17
JP5992096B2 (ja) 2016-09-14
CL2014002847A1 (es) 2015-01-30
JP2015518018A (ja) 2015-06-25
KR101666293B1 (ko) 2016-10-13
TW201402564A (zh) 2014-01-16
EP2855455B1 (en) 2017-11-08
MX2014014468A (es) 2015-02-12
CA2868240A1 (en) 2013-12-05
PH12014502294A1 (en) 2014-12-15
ZA201407695B (en) 2016-08-31
SG11201406890YA (en) 2014-11-27
US20150148332A1 (en) 2015-05-28
EP2855455A1 (en) 2015-04-08
WO2013178572A1 (en) 2013-12-05
CO7091174A2 (es) 2014-10-21
IL235829A0 (en) 2015-02-01
BR112014026828A2 (pt) 2017-06-27
PE20142366A1 (es) 2015-01-10
CR20140481A (es) 2014-11-17
AU2013269800A1 (en) 2014-10-09
US9394311B2 (en) 2016-07-19
CN104364249A (zh) 2015-02-18
KR20150027143A (ko) 2015-03-11

Similar Documents

Publication Publication Date Title
AR091185A1 (es) Derivados de 1,2,4-triazol
AR088449A1 (es) Benzilindazoles sustituidos
AR094557A1 (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn
AR090488A1 (es) Derivados de n-ciclobutilbenzamida, un proceso para su obtencion, intermediarios para su sintesis, composiciones pesticidas y farmaceuticas que los comprenden y metodos para controlar daños debidos a una plaga y/u hongos
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR089699A1 (es) Imidazoles y pirazoles fusionados sustituidos y sus usos
ES2620668T3 (es) Derivados de amidas y sulfonamidas amido espirocíclicas
AR092568A1 (es) Derivados triciclicos de quinolinas y de quinoxalinas
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
AR087711A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y uso de los mismos para el tratamiento de trastornos neurodegenerativos
PE20130376A1 (es) [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer
AR110498A1 (es) DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5
ES2603931T3 (es) Compuestos de triazolo
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR087771A1 (es) Moduladores de la pde10
ES2626801T3 (es) Compuestos de triazolopiridina como inhibidores de pde10a
AR095708A1 (es) Indazoles sustituidos con diaminoheteroarilo
MX373022B (es) Inhibidores de kv1.3 y su aplicacion medica.
AR093758A1 (es) Inhibidores de aril lactama quinasa
AR097755A1 (es) Derivados sustituidos de fenilalanina como moduladores del factor xia
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
AR102544A1 (es) Compuestos derivados de dihidrohidantoína como herbicidas

Legal Events

Date Code Title Description
FB Suspension of granting procedure